These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11167840)

  • 1. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.
    Chiriva-Internati M; Du J; Cannon M; Barlogie B; Yi Q
    Br J Haematol; 2001 Feb; 112(2):410-20. PubMed ID: 11167840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
    Wen YJ; Barlogie B; Yi Q
    Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
    Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
    J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
    Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
    Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
    Chiriva-Internati M; Wang Z; Xue Y; Bumm K; Hahn AB; Lim SH
    Eur J Immunol; 2001 Aug; 31(8):2277-83. PubMed ID: 11477539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model.
    Freeman LM; Lam A; Petcu E; Smith R; Salajegheh A; Diamond P; Zannettino A; Evdokiou A; Luff J; Wong PF; Khalil D; Waterhouse N; Vari F; Rice AM; Catley L; Hart DN; Vuckovic S
    J Immunol; 2011 Oct; 187(8):3987-96. PubMed ID: 21908738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.
    Azuma T; Otsuki T; Kuzushima K; Froelich CJ; Fujita S; Yasukawa M
    Clin Cancer Res; 2004 Nov; 10(21):7402-12. PubMed ID: 15534117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
    Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
    Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
    Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M
    J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor is critical for cytolytic T cell activity against allospecific hepatocytes and splenic targets in major histocompatibility complex class I disparate graft versus host disease.
    Ali S; Starwalt R; Kreck J; Whittington B; Brown GR
    J Interferon Cytokine Res; 2011 May; 31(5):423-31. PubMed ID: 21091241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
    Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
    J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
    Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
    Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets.
    Smyth MJ; Norihisa Y; Ortaldo JR
    J Immunol; 1992 Jan; 148(1):55-62. PubMed ID: 1345790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
    Hong S; Qian J; Yang J; Li H; Kwak LW; Yi Q
    Cancer Res; 2008 Oct; 68(20):8456-64. PubMed ID: 18922919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.